

ESPI REPORT NO. 29/2026 | 28 September 2026 | Signing of an agreement with PARP for funding under the HYBOLIC project

Current Report No. 29/2026

Legal basis: Article 17(1) of the MAR Regulation – inside information

With reference to Current Report No. 55/2025, the Management Board of Scope Fluidics S.A. ("**Scope**") announces that Hybolic sp. z o.o. ("**Hybolic**"), a wholly-owned subsidiary of Scope developing the HYBOLIC project, has entered into an agreement ("**Agreement**") with the Polish Agency for Enterprise Development ("**PARP**") concerning the granting by PARP of funding of up to PLN 14.4 million ("**Funding**") for the project entitled "Innovative system for simultaneous measurement of insulin and glucose concentrations using a composite biosensor, developed for personalised therapy of metabolic diseases" ("**Project**"). The total Project costs reported in the Funding application amount to PLN 24.1 million. The lower amount of Funding compared with that presented in Current Report No. 55/2025 results from a change in Hybolic's classification from a small to a medium-sized enterprise, which occurred between the submission of the application and the signing of the Agreement.

The Project focuses on the development of a hybrid biosensor system for monitoring insulin and glucose concentrations in interstitial fluid ("**System**"). The technology being developed under the Project offers high stability, specificity and reusability compared with traditional enzymatic biosensors. According to the assumptions, the System will integrate advanced biosensors with artificial intelligence algorithms, enabling real-time personalisation of therapy for type 1 and type 2 diabetes and insulin resistance, as well as optimisation of therapeutic strategies. The System is intended to constitute a comprehensive tool for therapy management in outpatient settings and to support the development of diagnostics and treatment of metabolic diseases. The Project provides for the development of a wearable device, and the team's intention is for the System to enable simultaneous measurement of glucose and insulin.

Under the Agreement, the Funding will be disbursed in tranches in accordance with the Project schedule, subject to Hybolic achieving the objectives specified in the Agreement. Taking into account that the schedule set out in the Project covers activities planned over a long-term horizon, i.e. until the end of Q1 2029, and also taking into account the fact that the baseline product development scenario under the HYBOLIC project assumes the development of a Point-of-Care (PoC) device, as well as the fact that the HYBOLIC project is at an early stage of development and that research and development activities, due to their nature, are difficult to plan with precision, particularly over the long term, the Management Board is unable to predict what portion of the Funding will actually be provided to Hybolic.

At the same time, given that almost 15 months have elapsed since the Funding application was submitted, Hybolic will apply to PARP for approval of an update to the Project schedule submitted with the application. Changes to R&D project schedules, particularly at a very early stage of development, are an inherent feature of such projects; however, it cannot be ruled out that the changes submitted by Hybolic may affect the amount or timing of receipt of the Funding.